ScholarLens Back to search
2014•Palliative MedicineRequires access

The use of aprepitant in a case of refractory nausea and vomiting

Lucy Lowery, Inga Andrew, Sarah E. Gill, Mark Andrew Lee

Open publisher page 4 citations

Abstract

BACKGROUND: This case report describes a patient whose refractory nausea and vomiting significantly improved with the use of aprepitant, a neurokinin receptor antagonist currently only licensed for short-term use in chemotherapy-induced nausea and vomiting. CASE PRESENTATION: A patient with breast cancer and meningeal metastases had an 18-month history of nausea and vomiting refractory to a number of antiemetics commonly used in palliative care. The nausea and vomiting resolved after receiving two doses of the drug aprepitant. CASE MANAGEMENT AND OUTCOME: Maintenance antiemetic treatment with aprepitant was continued over a 5-month period with no recurrence of nausea and vomiting, and no observed side effects. CONCLUSIONS: Aprepitant has a potential role as an antiemetic for refractory symptoms within the palliative-care setting.

About this research paper

What this paper is about

BACKGROUND: This case report describes a patient whose refractory nausea and vomiting significantly improved with the use of aprepitant, a neurokinin receptor antagonist currently only licensed for short-term use in chemotherapy-induced nausea and vomiting. CASE PRESENTATION: A patient with breast cancer and meningeal metastases had an 18-month history of nausea and vomiting refractory to a number of antiemetics commonly used in palliative care. The nausea and vomiting resolved after receiving two doses of the drug aprepitant. CASE MANAGEMENT AND OUTCOME: Maintenance antiemetic treatment with aprepitant was continued over a 5-month period with no recurrence of nausea and vomiting, and no observed side effects. CONCLUSIONS: Aprepitant has a potential role as an antiemetic for refractory symptoms within the palliative-care setting.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

BACKGROUND: This case report describes a patient whose refractory nausea and vomiting significantly improved with the use of aprepitant, a neurokinin receptor antagonist currently only licensed for short-term use in chemotherapy-induced nausea and vomiting. CASE PRESENTATION: A patient with breast cancer and meningeal metastases had an 18-month history of nausea and vomiting refractory to a number of antiemetics commonly used in palliative care. The nausea and vomiting resolved after receiving two doses of the drug aprepitant. CASE MANAGEMENT AND OUTCOME: Maintenance antiemetic treatment with aprepitant was continued over a 5-month period with no recurrence of nausea and vomiting, and no observed side effects. CONCLUSIONS: Aprepitant has a potential role as an antiemetic for refractory symptoms within the palliative-care setting.

Key concepts: Aprepitant, Nausea, Vomiting, Antiemetic, Medicine, Anesthesia, Refractory (planetary science), Palliative care

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
The use of aprepitant in a case of refractory nausea and vomiting — Research Paper | ScholarLens